Lithium

60 %
40 %
Information about Lithium
Health & Medicine

Published on August 7, 2008

Author: shahparind

Source: slideshare.net

Description

Facts to remember about lithium

LITHIUM IN PSYCHIATRY

IN PSYCHIATRY

Class This drug is a member of the following class: Mood stabilizer (?) Antimanic Hematopoietic

DOSAGE

Dosing Information a)  Lithium Carbonate Adult Bipolar disorder, manic episode 1)  acute, 1800 mg/day ORALLY in 2-3 divided doses; desired serum lithium level ranging between 1-1.5 mEq/L 2)  maintenance, 900-1200 mg/day ORALLY in 2-3 divided doses; desired serum lithium levels ranging between 0.6-1.2 mEq/L

Adult Bipolar disorder,

manic episode 1)  acute, 1800 mg/day ORALLY in 2-3 divided doses; desired serum lithium level ranging between 1-1.5 mEq/L 2)  maintenance, 900-1200 mg/day ORALLY in 2-3 divided doses; desired serum lithium levels ranging between 0.6-1.2 mEq/L

Dosing Information a)  Lithium Carbonate Cluster headache 300-900 mg/day ORALLY (divided doses); keep serum concentration below 1.2 mEq/L

Cluster headache 300-900 mg/day ORALLY (divided doses); keep serum concentration below 1.2 mEq/L

Dosing Information a)  Lithium Carbonate Graves' disease; Adjunct 900 mg/day ORALLY for 6 days beginning on the day of radioiodine administration

Graves' disease; Adjunct 900 mg/day ORALLY for 6 days beginning on the day of radioiodine administration

Pediatric Safety and effectiveness in pediatric patients below the age of 12 have not been established Conduct disorder, adolescent-onset type: dose 300-2100 mg/day ORALLY (divided doses); desired serum lithium level ranging between 0.8-1.2 mEq/L

Safety and effectiveness in pediatric patients below the age of 12 have not been established

Conduct disorder, adolescent-onset type: dose

300-2100 mg/day ORALLY (divided doses); desired serum lithium level ranging between 0.8-1.2 mEq/L

USES IN PSYCHIATRY

Clinical Applications Lithium Carbonate FDA Approved Indications a)  Bipolar disorder, manic episode Non-FDA Approved Indications a)  Cluster headache b)  Conduct disorder, adolescent-onset type c)  Graves' disease; Adjunct

Lithium Carbonate

FDA Approved Indications a)  Bipolar disorder, manic episode

Non-FDA Approved Indications a)  Cluster headache b)  Conduct disorder, adolescent-onset type c)  Graves' disease; Adjunct

 

Bipolar disorder 1)  ACUTE MANIA THE USUAL RECOMMENDED DOSE FOR ACUTE MANIA IS 1800 MILLIGRAMS/DAY IN DIVIDED DOSES TO ACHIEVE THE DESIRED SERUM LEVEL OF 1 TO 1.5 MILLIMOLE/LITER DOSES SHOULD BE INDIVIDUALIZED TO APPROPRIATE SERUM LEVEL AND PATIENT RESPONSE. UNTIL THE SERUM LEVEL AND THE PATIENT'S CLINICAL CONDITION ARE STABLE, LITHIUM CONCENTRATION SHOULD BE DETERMINED TWICE WEEKLY.

THE USUAL RECOMMENDED DOSE FOR ACUTE MANIA IS 1800 MILLIGRAMS/DAY IN DIVIDED DOSES TO ACHIEVE THE DESIRED SERUM LEVEL OF 1 TO 1.5 MILLIMOLE/LITER

DOSES SHOULD BE INDIVIDUALIZED TO APPROPRIATE SERUM LEVEL AND PATIENT RESPONSE. UNTIL THE SERUM LEVEL AND THE PATIENT'S CLINICAL CONDITION ARE STABLE, LITHIUM CONCENTRATION SHOULD BE DETERMINED TWICE WEEKLY.

MANIA - MAINTENANCE DOSE When manic symptoms subside, the dose of lithium should be reduced to maintain a serum concentration of 0.6 to 1.2 millimole/liter Usual maintenance doses are 900 to 1200 milligrams/day; dosage will vary between individuals. Serum lithium concentrations should be monitored at least every 2 months. Patients with lithium levels of 0.8 to 1 millimole/liter had fewer relapses than patients with lithium levels of 0.4 to 0.6 millimole/liter MOST CLINICIANS RECOMMEND AN INITIAL DOSE OF 900 TO 1200 MILLIGRAMS DAILY. SINGLE DAILY DOSING HAS BEEN SHOWN TO BE AS TOLERABLE AS DIVIDED DOSING IN OUTPATIENTS ON MAINTENANCE LITHIUM

When manic symptoms subside, the dose of lithium should be reduced to maintain a serum concentration of 0.6 to 1.2 millimole/liter

Usual maintenance doses are 900 to 1200 milligrams/day; dosage will vary between individuals.

Serum lithium concentrations should be monitored at least every 2 months.

Patients with lithium levels of 0.8 to 1 millimole/liter had fewer relapses than patients with lithium levels of 0.4 to 0.6 millimole/liter

MOST CLINICIANS RECOMMEND AN INITIAL DOSE OF 900 TO 1200 MILLIGRAMS DAILY. SINGLE DAILY DOSING HAS BEEN SHOWN TO BE AS TOLERABLE AS DIVIDED DOSING IN OUTPATIENTS ON MAINTENANCE LITHIUM

IMPORTANT NOTE Immediate release tablets are usually given 3 or 4 times daily while controlled release tablets are usually given twice daily. Lithium tolerance is greater during the acute manic phase and decreases when manic symptoms subside

Immediate release tablets are usually given 3 or 4 times daily while controlled release tablets are usually given twice daily.

Lithium tolerance is greater during the acute manic phase and decreases when manic symptoms subside

Dosage in Renal Failure The following dosage reduction has been recommended in patients with renal failure: glomerular filtration rate (GFR) greater than 50 milliliters/minute, no dosage reduction; GFR 10 to 50 milliliters/minute, 50 to 75% of the usual dose; GFR less than 10 milliliters/minute, 25 to 50% of the usual dose given at the normal dosage interval.   Lithium clearance in patients with chronic renal disease decreased by a mean of 25

The following dosage reduction has been recommended in patients with renal failure: glomerular filtration rate (GFR) greater than 50 milliliters/minute, no dosage reduction; GFR 10 to 50 milliliters/minute, 50 to 75% of the usual dose; GFR less than 10 milliliters/minute, 25 to 50% of the usual dose given at the normal dosage interval.

  Lithium clearance in patients with chronic renal disease decreased by a mean of 25

Dosage in Geriatric Patients It may be necessary to decrease lithium dosage by as much as 50% in elderly patients to compensate for reduced clearance Geriatric patients should be treated with initial lower doses of lithium and titrated to the desired therapeutic response. Some reports have indicated that elderly patients may develop symptoms of lithium toxicity at therapeutic serum levels

It may be necessary to decrease lithium dosage by as much as 50% in elderly patients to compensate for reduced clearance

Geriatric patients should be treated with initial lower doses of lithium and titrated to the desired therapeutic response. Some reports have indicated that elderly patients may develop symptoms of lithium toxicity at therapeutic serum levels

Dosage Adjustment During Dialysis maintenance dose should be given following hemodialysis Serum lithium concentrations following dialysis are useful as a dosing guideline

maintenance dose should be given following hemodialysis Serum lithium concentrations following dialysis are useful as a dosing guideline

Pediatric Dosage Bipolar disorder Use in patients less than 12 years old is not recommended due to a lack of information regarding safety and effectiveness Lithium carbonate monotherapy (32 to 63 milligrams/kilogram/day) was reported effective in the treatment of manic episodes with psychotic features in prepubertal children (6 to 12 years of age) in an open study (Varanka, 1988). All of 10 children treated improved after an average of 11 days of lithium therapy (range, 3 to 24 days). Therapeutic lithium levels (0.6 to 1.4 millimole/liter) were achieved within 3 to 5 days in all children. Controlled studies are required to further evaluate the efficacy of lithium in this patient population.

Bipolar disorder Use in patients less than 12 years old is not recommended due to a lack of information regarding safety and effectiveness

Lithium carbonate monotherapy (32 to 63 milligrams/kilogram/day) was reported effective in the treatment of manic episodes with psychotic features in prepubertal children (6 to 12 years of age) in an open study (Varanka, 1988). All of 10 children treated improved after an average of 11 days of lithium therapy (range, 3 to 24 days). Therapeutic lithium levels (0.6 to 1.4 millimole/liter) were achieved within 3 to 5 days in all children. Controlled studies are required to further evaluate the efficacy of lithium in this patient population.

Pharmacoinetics

Onset and Duration Onset- Initial Response   Mania, oral: 7 to 14 days

Onset- Initial Response

  Mania, oral: 7 to 14 days

Drug Concentration Levels   Therapeutic Drug Concentration ACUTE MANIA/HYPOMANIA a)  1 to 1.5 millimol/liter PROPHYLAXIS AND MAINTENANCE THERAPY OF MANIA a)  0.6 to 1.2 mmol/L DEPRESSION a)  0.3 to 0.6 millimol/liter

  Therapeutic Drug Concentration

ACUTE MANIA/HYPOMANIA a)  1 to 1.5 millimol/liter

PROPHYLAXIS AND MAINTENANCE THERAPY OF MANIA a)  0.6 to 1.2 mmol/L

DEPRESSION a)  0.3 to 0.6 millimol/liter

Time to Peak Concentration Oral: 0.5 to 2 hours Due to slow tissue distribution, complete plasma-tissue equilibration and steady-state plasma levels usually require 5 to 10 days of therapy

Oral: 0.5 to 2 hours

Due to slow tissue distribution, complete plasma-tissue equilibration and steady-state plasma levels usually require 5 to 10 days of therapy

Absorption A)  Bioavailability LIQUID VERSUS SOLID: No significant difference in bioavailability exists following oral administration of lithium carbonate capsules or lithium citrate liquid. Liquid lithium achieves higher peak levels and a faster time-to-peak than tablets SLOW-RELEASE VERSUS STANDARD FORMULATION: Standard lithium carbonate and the slow-release form provide equivalent steady-state lithium levels

LIQUID VERSUS SOLID: No significant difference in bioavailability exists following oral administration of lithium carbonate capsules or lithium citrate liquid. Liquid lithium achieves higher peak levels and a faster time-to-peak than tablets SLOW-RELEASE VERSUS STANDARD FORMULATION: Standard lithium carbonate and the slow-release form provide equivalent steady-state lithium levels

Distribution - Distribution Sites   Protein Binding a)  None

  Protein Binding a)  None

Distribution - Distribution Sites OTHER DISTRIBUTION SITES a)  Fluids, good 1)  Lithium distributes throughout intracellular and extracellular fluids and is not protein bound (Baer, 1973). b)  Placenta, good 1)  Lithium passes into breast milk and across the placental barrier (Prod Info Eskalith(R), 2002; Schou & Amdisen, 1973a). c)  Tissues, good 1)  Lithium undergoes widespread tissue localization and is taken up rapidly by the liver and kidney, and more slowly by muscle, bone and brain

OTHER DISTRIBUTION SITES a)  Fluids, good 1)  Lithium distributes throughout intracellular and extracellular fluids and is not protein bound (Baer, 1973). b)  Placenta, good 1)  Lithium passes into breast milk and across the placental barrier (Prod Info Eskalith(R), 2002; Schou & Amdisen, 1973a). c)  Tissues, good 1)  Lithium undergoes widespread tissue localization and is taken up rapidly by the liver and kidney, and more slowly by muscle, bone and brain

Distribution Kinetics 1)  Volume of Distribution 0.7 to 1.4 liters/kilogram

0.7 to 1.4 liters/kilogram

Distribution Kinetics Volume of Distribution Relative volume of distribution of lithium was studied in young and elderly patients and patients with renal insufficiency. In young patients with normal renal function (age 23 to 28 years), the volume of distribution was 120.45% of body weight (ie, 0.8 to 0.9 L/kg). In elderly patients with normal renal function (age 52 to 65 years), the volume of distribution was 92.65% of body weight (ie, 0.7 to 0.8 L/kg). In patients with renal insufficiency (58 to 65 years), the volume of distribution was 81% of body weight). 2)  Lithium distribution may be related to sympathetic adrenal activity and sodium distribution in manic patients. Tissue lithium concentrations may continue to increase for hours after plasma lithium concentrations have peaked

Relative volume of distribution of lithium was studied in young and elderly patients and patients with renal insufficiency. In young patients with normal renal function (age 23 to 28 years), the volume of distribution was 120.45% of body weight (ie, 0.8 to 0.9 L/kg). In elderly patients with normal renal function (age 52 to 65 years), the volume of distribution was 92.65% of body weight (ie, 0.7 to 0.8 L/kg). In patients with renal insufficiency (58 to 65 years), the volume of distribution was 81% of body weight). 2)  Lithium distribution may be related to sympathetic adrenal activity and sodium distribution in manic patients. Tissue lithium concentrations may continue to increase for hours after plasma lithium concentrations have peaked

Metabolism Metabolism Sites and Kinetics 1)  Urine, almost entirely

Metabolism Sites and Kinetics 1)  Urine, almost entirely

Excretion Kidney Renal Clearance (rate) 10 to 37 milliliters/minute   Renal Excretion (%) 89% to 98% 1)  Increases in lithium serum levels occur with sodium depletion or with a low salt diet secondary to enhanced proximal tubular reabsorption of the lithium ion. Renal excretion of lithium does not appear to be enhanced by increasing water intake or acidification of urine . 2)  Lean body weight and creatinine clearance are important predictors of lithium clearance

Kidney

Renal Clearance (rate) 10 to 37 milliliters/minute

  Renal Excretion (%) 89% to 98%

1)  Increases in lithium serum levels occur with sodium depletion or with a low salt diet secondary to enhanced proximal tubular reabsorption of the lithium ion. Renal excretion of lithium does not appear to be enhanced by increasing water intake or acidification of urine . 2)  Lean body weight and creatinine clearance are important predictors of lithium clearance

Excretion Total Body Clearance 1.13 mL/min/kg

Total Body Clearance 1.13 mL/min/kg

Excretion Total Body Clearance 1.13 mL/min/kg

Total Body Clearance 1.13 mL/min/kg

ddss

Excretion Other OTHER EXCRETION   FECES, insignificant

Other OTHER EXCRETION

  FECES, insignificant

Elimination Half-life Parent Compound 1)  ELIMINATION HALF-LIFE a)  14 to 24 hours 1)  Duration of lithium treatment had a direct effect on prolonging the elimination half-life. Plasma half-life in patients on lithium therapy for less than 1 year was 1.65 days compared with 2.43 days in patients on lithium for more than 1 year continuously 2)  Creatinine clearance, sodium clearance, and potassium clearance show significant correlation with lithium clearance 3)  The half-life of lithium in elderly patients may be as long as 36 hours. The reduction in lithium clearance correlates with decreased creatinine clearance. 4)  The elimination half-life of lithium in children 9 to 12 years of age was 17.9 hours after a single 300-milligram oral dose 5)  Significantly longer lithium elimination half-lives were reported in bipolar patients compared with unipolar patients using plasma and red blood cell-level monitoring. Half-life values using plasma were: Bipolar I: 2.4 days, Bipolar II: 1.5, Unipolar: 1.1; for RBC: Bipolar I: 2.0, Bipolar II: 1.5, Unipolar: 0.8

Parent Compound 1)  ELIMINATION HALF-LIFE a)  14 to 24 hours

1)  Duration of lithium treatment had a direct effect on prolonging the elimination half-life. Plasma half-life in patients on lithium therapy for less than 1 year was 1.65 days compared with 2.43 days in patients on lithium for more than 1 year continuously 2)  Creatinine clearance, sodium clearance, and potassium clearance show significant correlation with lithium clearance 3)  The half-life of lithium in elderly patients may be as long as 36 hours. The reduction in lithium clearance correlates with decreased creatinine clearance. 4)  The elimination half-life of lithium in children 9 to 12 years of age was 17.9 hours after a single 300-milligram oral dose 5)  Significantly longer lithium elimination half-lives were reported in bipolar patients compared with unipolar patients using plasma and red blood cell-level monitoring. Half-life values using plasma were: Bipolar I: 2.4 days, Bipolar II: 1.5, Unipolar: 1.1; for RBC: Bipolar I: 2.0, Bipolar II: 1.5, Unipolar: 0.8

Effects vs. Adverse Drug Effects

Serious Adverse Effects   Papillary thyroid carcinoma

  Papillary thyroid carcinoma

Serious Adverse Effects 1)  Ataxia 2)  Blurred vision 3)  Bradyarrhythmia (Severe) 4)  Cardiac dysrhythmia 5)  Coma 6)  Giddiness 7)  Hypotension 8)  Polyuria, Dilute, may be a sign of serious toxicity 9)  Pseudotumor cerebri, Increased intracranial pressure and papilledema 10)  Seizure, Epileptiform 11)  Sinus node dysfunction 12)  Tinnitus, May be signs of serious toxicity

1)  Ataxia 2)  Blurred vision 3)  Bradyarrhythmia (Severe) 4)  Cardiac dysrhythmia 5)  Coma 6)  Giddiness 7)  Hypotension 8)  Polyuria, Dilute, may be a sign of serious toxicity 9)  Pseudotumor cerebri, Increased intracranial pressure and papilledema 10)  Seizure, Epileptiform 11)  Sinus node dysfunction 12)  Tinnitus, May be signs of serious toxicity

Adverse Reactions Cardiovascular Effects Dermatologic Effects Endocrine/Metabolic Effects Gastrointestinal Effects Hematologic Effects Hepatic Effects Immunologic Effects Musculoskeletal Effects Neurologic Effects Ophthalmic Effects Otic Effects Psychiatric Effects Renal Effects Reproductive Effects Other

Cardiovascular Effects Dermatologic Effects Endocrine/Metabolic Effects Gastrointestinal Effects Hematologic Effects Hepatic Effects Immunologic Effects Musculoskeletal Effects Neurologic Effects Ophthalmic Effects Otic Effects Psychiatric Effects Renal Effects Reproductive Effects Other

Cardiovascular Effects Cardiovascular finding Edema Heart block Hypertension Myocarditis Sinus node dysfunction

Cardiovascular finding Edema Heart block Hypertension Myocarditis Sinus node dysfunction

Cardiovascular finding a)  In therapeutic doses, lithium produces reversible T WAVE FLATTENING,and rarely, VENTRICULAR ARRHYTHMIAS An estimated 28% to 40% of patients may experience atrioventricular block or other cardiac conduction abnormalities while receiving lithium. The changes are relatively benign, require no treatment, and do not require discontinuation of lithium.Lithium can be used safely in most patients with cardiac disease if the dose is adjusted to the rate of lithium excretion and lithium levels are monitored. Frequent electrocardiographic monitoring is recommended HYPERTENSION has been reported in 1 case 2)  Cardiac arrhythmias, hypotension, hypertension, peripheral circulatory collapse, bradycardia, myocarditis and sinus node dysfunction have occurred with lithium use and appear to be related to serum lithium levels.

a)  In therapeutic doses, lithium produces reversible T WAVE FLATTENING,and rarely, VENTRICULAR ARRHYTHMIAS An estimated 28% to 40% of patients may experience atrioventricular block or other cardiac conduction abnormalities while receiving lithium. The changes are relatively benign, require no treatment, and do not require discontinuation of lithium.Lithium can be used safely in most patients with cardiac disease if the dose is adjusted to the rate of lithium excretion and lithium levels are monitored. Frequent electrocardiographic monitoring is recommended HYPERTENSION has been reported in 1 case

2)  Cardiac arrhythmias, hypotension, hypertension, peripheral circulatory collapse, bradycardia, myocarditis and sinus node dysfunction have occurred with lithium use and appear to be related to serum lithium levels.

Edema Edema has occurred during lithium therapy and disappears upon reduction of the dose or discontinuation of the drug. This may be attributable to tubular reabsorption of sodium

Edema has occurred during lithium therapy and disappears upon reduction of the dose or discontinuation of the drug. This may be attributable to tubular reabsorption of sodium

Heart block An estimated 28% to 40% of patients may experience AV block or other CARDIAC CONDUCTION ABNORMALITIES while receiving lithium . The changes are relatively benign, require no treatment, and do not require discontinuation of the lithium therapy

An estimated 28% to 40% of patients may experience AV block or other CARDIAC CONDUCTION ABNORMALITIES while receiving lithium . The changes are relatively benign, require no treatment, and do not require discontinuation of the lithium therapy

Sinus node dysfunction Reversible and irreversible sinus node dysfunction have been reported with long- term lithium therapy

Reversible and irreversible sinus node dysfunction have been reported with long- term lithium therapy

Dermatologic Effects Alopecia Dermatological finding Folliculitis Nail damage Psoriasis Scaly skin

Alopecia Dermatological finding Folliculitis Nail damage Psoriasis Scaly skin

Endocrine/Metabolic Effects Autoimmune thyroiditis Body temperature above normal Body temperature finding Diabetes insipidus Disorder of fluid AND/OR electrolyte Endocrine finding Hypercalcemia Hyperglycemia Hyperkalemia Hyperosmolality, Serum Hyperparathyroidism Hyperthyroidism Hypoglycemia Hypokalemia Hypothermia Hypothyroidism Metabolic finding Papillary thyroid carcinoma Weight gain

Autoimmune thyroiditis Body temperature above normal Body temperature finding Diabetes insipidus Disorder of fluid AND/OR electrolyte Endocrine finding Hypercalcemia Hyperglycemia Hyperkalemia Hyperosmolality, Serum Hyperparathyroidism Hyperthyroidism Hypoglycemia Hypokalemia Hypothermia Hypothyroidism Metabolic finding Papillary thyroid carcinoma Weight gain

Autoimmune thyroiditis Thyroiditis is thought to occur in combination with an autoimmune response with lithium playing a contributory role. Lithium induced thyroid dysfunction may involve worsening of an underlying autoimmune thyroiditis possibly caused by shifts in T lymphocyte subpopulations. However, the results of one controlled study suggest that long-term lithium therapy is not associated with an increased incidence of thyroid autoimmunity in patients receiving lithium for the treatment of affective disorders

Thyroiditis is thought to occur in combination with an autoimmune response with lithium playing a contributory role. Lithium induced thyroid dysfunction may involve worsening of an underlying autoimmune thyroiditis possibly caused by shifts in T lymphocyte subpopulations.

However, the results of one controlled study suggest that long-term lithium therapy is not associated with an increased incidence of thyroid autoimmunity in patients receiving lithium for the treatment of affective disorders

Diabetes insipidus Symptoms of NEPHROGENIC DIABETES INSIPIDUS (POLYURIA, POLYDIPSIA, NOCTURIA) have been reported with lithium use and may be related to serum lithium levels. (In addition, chronic renal failure may predispose a patient to develop persistent nephrogenic diabetes insipidus. While occurrence is uncommon and may disappear within weeks of drug discontinuation, serious and fatal complications have rarely developed. Chlorthalidone, hydrochlorothiazide, or amiloride have been used to manage symptoms, and lithium dosing schedules that produce therapeutic response with minimum trough levels (ie, once daily regimens) may reduce the risk for developing lithium-induced polyuria

Symptoms of NEPHROGENIC DIABETES INSIPIDUS (POLYURIA, POLYDIPSIA, NOCTURIA) have been reported with lithium use and may be related to serum lithium levels. (In addition, chronic renal failure may predispose a patient to develop persistent nephrogenic diabetes insipidus. While occurrence is uncommon and may disappear within weeks of drug discontinuation, serious and fatal complications have rarely developed. Chlorthalidone, hydrochlorothiazide, or amiloride have been used to manage symptoms, and lithium dosing schedules that produce therapeutic response with minimum trough levels (ie, once daily regimens) may reduce the risk for developing lithium-induced polyuria

Hyperthyroidism Thyrotoxicosis is also a complication of lithium carbonate therapy

Thyrotoxicosis is also a complication of lithium carbonate therapy

Hypothyroidism -common Lithium has been reported to suppress thyroid function, in 42% of patients , cause subclinical hypothyroidism in up to 23%, and cause overt hypothyroidism in between 8% to 19% of patients. The prevalence appears to be higher in women at 14% as compared to men at only 4.5% These effects occur 3 to 6 weeks after starting treatment and can be controlled with thyroid medication, although thyroid function tests may normalize over 6 months to 2 years with continuous lithium treatment

Lithium has been reported to suppress thyroid function, in 42% of patients , cause subclinical hypothyroidism in up to 23%, and cause overt hypothyroidism in between 8% to 19% of patients. The prevalence appears to be higher in women at 14% as compared to men at only 4.5% These effects occur 3 to 6 weeks after starting treatment and can be controlled with thyroid medication, although thyroid function tests may normalize over 6 months to 2 years with continuous lithium treatment

Weight gain Lithium maintenance treatment has been associated with weight gain, however, there are conflicting reports when chronic psychotic patients were studied. In a study regarding weight gain in conjunction with compliance, weight gain was stated to be a disturbing finding by patients

Lithium maintenance treatment has been associated with weight gain, however, there are conflicting reports when chronic psychotic patients were studied. In a study regarding weight gain in conjunction with compliance, weight gain was stated to be a disturbing finding by patients

Gastrointestinal Effects Aversion to food or drink Excessive salivation Gastrointestinal tract finding Hyposecretion of salivary gland

Aversion to food or drink Excessive salivation Gastrointestinal tract finding Hyposecretion of salivary gland

Hematologic Effects Leukocytosis, thrombocytosis and thrombosis have been reported with lithium therapy

Leukocytosis, thrombocytosis and thrombosis have been reported with lithium therapy

Hepatic Effects Ascites Hyperbilirubinemia

Ascites Hyperbilirubinemia

Immunologic Effects Myasthenia gravis and systemic lupus erythematosus have been reported with lithium therapy

Myasthenia gravis and systemic lupus erythematosus have been reported with lithium therapy

Neurologic Effects Cerebellar disorder Cognitive function finding Delirium Extrapyramidal sign Headache Movement disorder Neurological finding Nystagmus Peripheral neuropathy Pseudotumor cerebri Seizure Tremor

Cerebellar disorder Cognitive function finding Delirium Extrapyramidal sign Headache Movement disorder Neurological finding Nystagmus Peripheral neuropathy Pseudotumor cerebri Seizure Tremor

Delirium Organic brain syndrome and DELIRIUM has occurred with lithium carbonate. When combined with a neuroleptic, encephalopathy occurred. Lithium has also been associated with neurotoxicity when used in treatment of a manic episode and should be discontinued prior to electroconvulsive for the organic brain syndrome patient

Organic brain syndrome and DELIRIUM has occurred with lithium carbonate.

When combined with a neuroleptic, encephalopathy occurred.

Lithium has also been associated with neurotoxicity when used in treatment of a manic episode and should be discontinued prior to electroconvulsive for the organic brain syndrome patient

Extrapyramidal sign Extrapyramidal side effects occur rarely with lithium therapy. Reported effects include Parkinsonian-like symptoms, rigidity, and choreoathetosis that have occurred at both toxic and therapeutic serum concentrations. Lithium in combination with haloperidol therapy has resulted in rare cases of extrapyramidal toxicity, some of which have resulted in prolonged or permanent sequelae

Extrapyramidal side effects occur rarely with lithium therapy.

Reported effects include Parkinsonian-like symptoms, rigidity, and choreoathetosis that have occurred at both toxic and therapeutic serum concentrations.

Lithium in combination with haloperidol therapy has resulted in rare cases of extrapyramidal toxicity, some of which have resulted in prolonged or permanent sequelae

Headache Lithium treatment has been associated with the development of generalized headache, worsening of cluster headache, and exacerbation of migraine headache

Lithium treatment has been associated with the development of generalized headache, worsening of cluster headache, and exacerbation of migraine headache

Movement disorder Neurological movement disorders associated with lithium use include ASTERIXIS, MYOCLONUS, and CHOREA

Neurological movement disorders associated with lithium use include ASTERIXIS, MYOCLONUS, and CHOREA

Neurological finding Cerebellar disorders, cognitive findings, extrapyramidal symptoms, headaches, movement disorders, pseudotumor cerebri, seizures, sleep disorders and peripheral nerve impairment are associated with lithium use

Cerebellar disorders, cognitive findings, extrapyramidal symptoms, headaches, movement disorders, pseudotumor cerebri, seizures, sleep disorders and peripheral nerve impairment are associated with lithium use

Peripheral neuropathy Lithium appeared to impair peripheral nerve function as measured by electroneurographic parameters including motor nerve conduction velocity (NCV) of peroneal and median nerves, sensory nerve conduction velocity of sural and median nerves, amplitude of motor potential of peroneal and median nerves, and amplitude of sensory action potential of the median nerve at the wrist and the sural nerve. Patients receiving lithium (n=34) were compared to affective controls (n=20), healthy controls (n=54), and pretreatment values (n=12). Significant differences were seen in the lithium treated patients as compared to controls in the motor NCV (peroneal nerve)(p less than 0.05), the motor action potential amplitude (peroneal nerve)(p less than 0.05), and the sensory action potential amplitude (sural and median nerve)(p less than 0.001). Significant differences were also seen in lithium-treated patients as compared to pretreatment values for peroneal motor NCV (p less than 0.01), sural and median sensory NCV (p less than 0.001, p less than 0.02, respectively), motor action potential amplitude of the peroneal nerve (p less than 0.05), and sensory action potential amplitude of the sural and median nerve

Lithium appeared to impair peripheral nerve function as measured by electroneurographic parameters including motor nerve conduction velocity (NCV) of peroneal and median nerves, sensory nerve conduction velocity of sural and median nerves, amplitude of motor potential of peroneal and median nerves, and amplitude of sensory action potential of the median nerve at the wrist and the sural nerve. Patients receiving lithium (n=34) were compared to affective controls (n=20), healthy controls (n=54), and pretreatment values (n=12). Significant differences were seen in the lithium treated patients as compared to controls in the motor NCV (peroneal nerve)(p less than 0.05), the motor action potential amplitude (peroneal nerve)(p less than 0.05), and the sensory action potential amplitude (sural and median nerve)(p less than 0.001). Significant differences were also seen in lithium-treated patients as compared to pretreatment values for peroneal motor NCV (p less than 0.01), sural and median sensory NCV (p less than 0.001, p less than 0.02, respectively), motor action potential amplitude of the peroneal nerve (p less than 0.05), and sensory action potential amplitude of the sural and median nerve

Seizure Major motor seizures with associated neurological disturbances have occurred in patients receiving therapeutic doses of lithium carbonate with or without toxic serum levels. No mechanism of action has been elucidated for lithium induced seizures. Patients at risk of seizure should be given lithium with caution

Major motor seizures with associated neurological disturbances have occurred in patients receiving therapeutic doses of lithium carbonate with or without toxic serum levels. No mechanism of action has been elucidated for lithium induced seizures. Patients at risk of seizure should be given lithium with caution

Tremor Persistent fine, rapid tremors occur in 30 to 50% of patients with therapeutic plasma levels. The tremor is a fast-frequency action tremor, which is exacerbated by tension, anxiety, fatigue, caffeine, and adrenergic stimulation, and is characterized by fine, jerky movements, especially in the fingers . Lithium tremor may persist at rest in some patients. Beta-blockers have been effective in the treatment of lithium-induced tremors

Persistent fine, rapid tremors occur in 30 to 50% of patients with therapeutic plasma levels. The tremor is a fast-frequency action tremor, which is exacerbated by tension, anxiety, fatigue, caffeine, and adrenergic stimulation, and is characterized by fine, jerky movements, especially in the fingers . Lithium tremor may persist at rest in some patients. Beta-blockers have been effective in the treatment of lithium-induced tremors

Ophthalmic Effects Degenerative disorder of macula Eye / vision finding Oculogyric crisis Ophthalmoplegia

Degenerative disorder of macula Eye / vision finding Oculogyric crisis Ophthalmoplegia

Otic Effects Tinnitus

Tinnitus

Psychiatric Effects Mania Psychiatric sign or symptom Psychotic disorder Sleep disorder

Mania Psychiatric sign or symptom Psychotic disorder Sleep disorder

Mania Lithium toxicity has been reported to mimic manic states

Lithium toxicity has been reported to mimic manic states

Psychiatric sign or symptom Mania, psychosis (as seen in Capgras Syndrome and visual hallucinations) as well as worsening of organic brain syndromes have occurred with lithium use. These effects appear to be related to serum lithium levels. Patients with severe psychosis and anxiety may be at greater risk to develop lithium toxicity at therapeutic blood levels. The Capgras Syndrome denotes the delusional misidentification of familiar individuals as impostors or doubles

Mania, psychosis (as seen in Capgras Syndrome and visual hallucinations) as well as worsening of organic brain syndromes have occurred with lithium use. These effects appear to be related to serum lithium levels. Patients with severe psychosis and anxiety may be at greater risk to develop lithium toxicity at therapeutic blood levels.

The Capgras Syndrome denotes the delusional misidentification of familiar individuals as impostors or doubles

Sleep disorder SLEEPWALKING and RESTLESS LEG SYNDROME have been reported with lithium use

SLEEPWALKING and RESTLESS LEG SYNDROME have been reported with lithium use

Renal Effects Diabetes insipidus, nephrotic syndrome, nephrotoxicity, elevated BUN and serum creatinine, glycosuria, albuminuria, and oliguria have been reported with lithium

Diabetes insipidus, nephrotic syndrome, nephrotoxicity, elevated BUN and serum creatinine, glycosuria, albuminuria, and oliguria have been reported with lithium

Effects in Pregnancy U.S. Food and Drug Administration's Pregnancy Category: Category D There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective

U.S. Food and Drug Administration's Pregnancy Category: Category D

There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective

Breastfeeding American Academy of Pediatrics Rating: Drugs that have been associated with significant effects on some nursing infants and should be given to nursing mothers with caution

American Academy of Pediatrics Rating: Drugs that have been associated with significant effects on some nursing infants and should be given to nursing mothers with caution

Adverse effects due to breastfeeding ( floppiness, cyanosis, heart murmur, T-wave changes on electrocardiography, lethargy, hypothermia ) have been reported in breastfeeding infants in association with maternal use of lithium ( dose of 600 mg to 1200 mg per day )

( floppiness, cyanosis, heart murmur, T-wave changes on electrocardiography, lethargy, hypothermia ) have been reported in breastfeeding infants in association with maternal use of lithium ( dose of 600 mg to 1200 mg per day )

Adverse effects due to breastfeeding It has been suggested that mothers on lithium therapy wishing to breast feed their infants should be either partially or completely discontinued from the drug because of the immature metabolizing systems of the infant

It has been suggested that mothers on lithium therapy wishing to breast feed their infants should be either partially or completely discontinued from the drug because of the immature metabolizing systems of the infant

Drug-Drug Interactions

Drug Interactions-major Acetophenazine Azosemide Bemetizide Bendroflumethiazide Benzthiazide Bromperidol Bumetanide Buthiazide Candesartan Cilexetil Canrenoate Chlorothiazide Chlorpromazine Chlorprothixene Chlorthalidone Clozapine Cyclothiazide

Acetophenazine Azosemide Bemetizide Bendroflumethiazide Benzthiazide Bromperidol Bumetanide Buthiazide

Candesartan Cilexetil Canrenoate Chlorothiazide Chlorpromazine Chlorprothixene Chlorthalidone Clozapine Cyclothiazide

Drug Interactions-major Domperidone Droperidol Flupenthixol Fluphenazine Furosemide Haloperidol Hydrochlorothiazide Hydroflumethiazide Indapamide Losartan

Domperidone Droperidol Flupenthixol Fluphenazine Furosemide

Haloperidol Hydrochlorothiazide Hydroflumethiazide Indapamide

Losartan

Drug Interactions-major Melperone Mesoridazine Methotrimeprazine Methyclothiazide Metolazone Molindone Olanzapine Penfluridol Periciazine Perphenazine Phenelzine Pimozide Pipamperone Pipotiazine Piretanide Polythiazide Prochlorperazine Promazine Promethazine

Melperone Mesoridazine Methotrimeprazine Methyclothiazide Metolazone Molindone Olanzapine

Penfluridol Periciazine Perphenazine Phenelzine Pimozide Pipamperone Pipotiazine Piretanide Polythiazide Prochlorperazine Promazine Promethazine

Drug Interactions-major Quinethazone Remoxipride Risperidone Sertindole Sibutramine Spironolactone Sulpiride Thiopropazate Thioproperazine Thioridazine Thiothixene Tiapride Torsemide Trichlormethiazide Trifluoperazine Triflupromazine Trimeprazine Valsartan Xipamide

Quinethazone Remoxipride Risperidone Sertindole Sibutramine Spironolactone Sulpiride

Thiopropazate Thioproperazine Thioridazine Thiothixene Tiapride Torsemide Trichlormethiazide Trifluoperazine Triflupromazine Trimeprazine Valsartan Xipamide

Drug Interactions-Diuretics

Drug Interactions-NSAID

Drug Interactions-ACE inhibitors

Drug Interactions-Calcium Channel Blockers

Drug Interactions-metronidazoles Concurrent use of metronidazole with lithium may provoke lithium toxicity due to reduced renal clearance . Patients receiving such combined therapy should be monitored closely

Concurrent use of metronidazole with lithium may provoke lithium toxicity due to reduced renal clearance . Patients receiving such combined therapy should be monitored closely

Drug Interactions- SSRIs

Drug Intoxications

Lithium Intoxications-clinical effects MILD: N/V, tremors, hyperreflexia, agitation, ataxia. MODERATE: CNS depression, rigidity, hypertonia, fasciculation SEVERE: Seizures, myoclonus, coma, and hypotension. Permanent neurologic injury (cerebellar or cognitive defects) possible. Neuroleptic malignant syndrome possible.

MILD: N/V, tremors, hyperreflexia, agitation, ataxia.

MODERATE: CNS depression, rigidity, hypertonia, fasciculation

SEVERE: Seizures, myoclonus, coma, and hypotension. Permanent neurologic injury (cerebellar or cognitive defects) possible. Neuroleptic malignant syndrome possible.

Lithium Intoxications-clinical effects Patients with chronic toxicity can develop severe symptoms even with mildly elevated serum levels Concomitant medications, concurrent illness, and increased age may precipitate toxicity.

Patients with chronic toxicity can develop severe symptoms even with mildly elevated serum levels

Concomitant medications, concurrent illness, and increased age may precipitate toxicity.

Lithium Intoxications-treatment Decontamination: Gastric lavage. Activated charcoal minimal adsorption. WHOLE BOWEL IRRIGATION - Used for a large or sustained release ingestion. Polyethylene glycol (orally or by NG tube) Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine

Decontamination: Gastric lavage. Activated charcoal minimal adsorption. WHOLE BOWEL IRRIGATION - Used for a large or sustained release ingestion. Polyethylene glycol (orally or by NG tube)

Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine

Lithium Intoxications-treatment Enhanced elimination: 0.9% NaCl 10-20 ml/kg bolus followed by twice maintenance fluid rates. Hemodialysis for moderate/severe exposure or rapidly rising levels Monitoring of patient: Vital signs, electrolytes, serial lithium levels, urinalysis, serum creatinine.

Enhanced elimination: 0.9% NaCl 10-20 ml/kg bolus followed by twice maintenance fluid rates. Hemodialysis for moderate/severe exposure or rapidly rising levels Monitoring of patient: Vital signs, electrolytes, serial lithium levels, urinalysis, serum creatinine.

Range Of Toxicity Effects more severe with chronic intoxication. Levels correlate poorly with toxicity Levels as high as 3 to 6 mEq/L have been noted in asymptomatic patients .

Effects more severe with chronic intoxication.

Levels correlate poorly with toxicity

Levels as high as 3 to 6 mEq/L have been noted in asymptomatic patients .

fff

gggg

 

 

fffff

 

 

sss

Add a comment

Related presentations

Related pages

Lithium – Wikipedia

Lithium hat an der Erdkruste einen Anteil von etwa 0,006 %. Es kommt damit etwas seltener als Zink, Kupfer und Wolfram sowie etwas häufiger als Kobalt ...
Read more

Lithium - Medizin Online

Lithium wird in als Tablette oder Filmtablette eingenommen. Nach der Einnahme der Tablette löst diese sich im Magen-Darm-Trakt auf und das Lithium wird frei.
Read more

Lithium - Onmeda: Medizin & Gesundheit

Lithium wird bei psychischen Erkrankungen, vor allem bei Störungen der Gefühlslage, eingesetzt. Hierzu gehört die Anwendung bei der sogenannten Man...
Read more

Lithium - DocCheck Flexikon

Klicken Sie hier, um einen neuen Artikel im DocCheck Flexikon anzulegen. Artikel schreiben. Letzte Autoren des Artikels:
Read more

Lithiumtherapie – Wikipedia

Bei der Lithiumtherapie wird Lithium in Form einiger seiner Salze bei bipolarer Störung, Manie oder Depressionen einerseits als Phasenprophylaktikum ...
Read more

Lithium - Wikipedia, the free encyclopedia

General properties; Name, symbol: lithium, Li: Appearance: silvery-white: Pronunciation / ˈ l ɪ θ i ə m / LI-thee-əm: Lithium in the periodic table
Read more

Lithium - chemie.de - Das Chemie Fachportal vom Labor bis ...

Lithium [ˈliːtiʊm] (von griechisch λίθος líthos „Stein“) ist ein chemisches Element mit dem Symbol Li und der Ordnungszahl 3. Den Namen ...
Read more

Lithium (Li) - chemische Eigenschaften, gesundheitliche ...

Eigenschaften. Lithium ist das erste Alkalimetall im Periodensystem der Elemente. In der Natur findet man es in einer Mischform der Isotope Li 6 und Li 7.
Read more

Lithium 3 Li - Seilnachts Periodensystem: Lithium

Das Element Lithium im Periodensystem von Thomas Seilnacht
Read more

Lithium - Social Software for Customer Community ...

Lithium social software provides on-demand, hosted forums, chats, and other social media marketing solutions for companies. Request a demo today!
Read more